Description
Visomitin (SKQ1) is a mitochondrial-targeted antioxidant with the high mitochondrion membrane penetrating ability and potent antioxidant capability.
Product information
CAS Number: 934826-68-3
Molecular Weight: 617.60
Formula: C36H42BrO2P
Chemical Name: [10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl]triphenylphosphanium bromide
Smiles: [Br-].CC1C(=O)C(CCCCCCCCCC[P+](C2C=CC=CC=2)(C2C=CC=CC=2)C2C=CC=CC=2)=CC(=O)C=1C
InChiKey: WYHFWTRUGAFNKW-UHFFFAOYSA-M
InChi: InChI=1S/C36H42O2P.BrH/c1-29-30(2)36(38)31(28-35(29)37)20-12-7-5-3-4-6-8-19-27-39(32-21-13-9-14-22-32,33-23-15-10-16-24-33)34-25-17-11-18-26-34;/h9-11,13-18,21-26,28H,3-8,12,19-20,27H2,1-2H3;1H/q+1;/p-1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 100 mg/mL (161.92 mM; Need ultrasonic). H2O : 3.33 mg/mL (5.39 mM; ultrasonic and warming and heat to 80°C).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
Direct treatment of tumor infiltrating leukocytes with Visomitin (SkQ1) does not influence their cytotoxicity against Panc02 cells. While Visomitin does not affect viability of the cell lines, this drug at 500 nM concentration reduces heavily the proliferation of human PDAC cells.
In Vivo:
Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice a decrease in KC in the group of continuous treatment with Visomitin (SkQ1). Treatment of the mice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the Visomitin treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. The Visomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.